WYC-210, a Tazarotene derivative, is a retinoid compound with lower anticancer activity[1].
WYC-210 (10 μM; 5 days) inhibits cell growth of B16-F1 TRC cells with an inhibition rate of 18.1%[1].
[1]. Cao, Xin, et al. Preparation of the retinoid compound and their application as anticancer agents. WO2017152725A1.
















